Total Payments
$146,029
2024 Payments
$122,339
Companies
13
Transactions
67
Medicare Patients
9,471
Medicare Billing
$714,607
Payment Breakdown by Category
Research$122,339 (83.8%)
Other$21,240 (14.5%)
Food & Beverage$1,567 (1.1%)
Travel$863.90 (0.6%)
Education$18.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $122,339 | 2 | 83.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,240 | 9 | 14.5% |
| Food and Beverage | $1,567 | 42 | 1.1% |
| Travel and Lodging | $863.90 | 13 | 0.6% |
| Education | $18.99 | 1 | 0.0% |
Payments by Type
Research
$122,339
2 transactions
General
$23,690
65 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $122,339 | 2 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $17,798 | 29 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $5,340 | 7 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $234.71 | 14 | $0 (2022) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $124.56 | 1 | $0 (2017) |
| Actelion Pharmaceuticals US, Inc. | $56.22 | 4 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $40.29 | 3 | $0 (2017) |
| Amgen Inc. | $34.54 | 2 | $0 (2017) |
| Abbott Laboratories | $13.94 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $12.72 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $122,339 | 2 | Eli Lilly and Company ($122,339) |
| 2022 | $88.25 | 2 | E.R. Squibb & Sons, L.L.C. ($69.26) |
| 2019 | $9,242 | 19 | SANOFI-AVENTIS U.S. LLC ($5,340) |
| 2018 | $8,499 | 11 | Regeneron Healthcare Solutions, Inc. ($8,470) |
| 2017 | $5,861 | 33 | Regeneron Healthcare Solutions, Inc. ($5,407) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $115,315.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 05/15/2024 | Eli Lilly and Company | — | — | In-kind items and services | $7,024.13 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 08/19/2022 | Regeneron Healthcare Solutions, Inc. | EVKEEZA (Biological) | Education | In-kind items and services | $18.99 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 02/03/2022 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $69.26 | General |
| 08/15/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,546.75 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/15/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/15/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Travel and Lodging | Cash or cash equivalent | $21.11 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/15/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Travel and Lodging | Cash or cash equivalent | $1.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/18/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,546.75 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/18/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Food and Beverage | In-kind items and services | $92.82 | General |
| Category: CARDIOVASCULAR | ||||||
| 07/18/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Travel and Lodging | Cash or cash equivalent | $6.73 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/25/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Travel and Lodging | In-kind items and services | $192.66 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/25/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $58.47 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/25/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $55.03 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/25/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $43.02 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/25/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $36.96 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/25/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $30.51 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/17/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Travel and Lodging | In-kind items and services | $169.12 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/17/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 06/17/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Travel and Lodging | In-kind items and services | $27.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 05/23/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,910.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 04/18/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Travel and Lodging | In-kind items and services | $293.67 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 04/18/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Travel and Lodging | In-kind items and services | $35.25 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/05/2018 | Regeneron Healthcare Solutions, Inc. | PRALUENT ALIROCUMAB INJECTION (Biological) | Travel and Lodging | In-kind items and services | $20.93 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/29/2018 | Regeneron Healthcare Solutions, Inc. | PRALUENT ALIROCUMAB INJECTION (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,572.50 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $122,339 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 2,459 | 3,308 | $813,082 | $177,512 |
| 2022 | 20 | 2,349 | 3,207 | $802,702 | $177,542 |
| 2021 | 20 | 2,475 | 3,644 | $860,483 | $197,682 |
| 2020 | 19 | 2,188 | 3,066 | $733,389 | $161,871 |
Total Patients
9,471
Total Services
13,225
Medicare Billing
$714,607
Procedure Codes
87
All Medicare Procedures & Services
87 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 613 | 1,075 | $288,100 | $102,044 | 35.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 336 | 343 | $212,043 | $17,209 | 8.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 132 | 162 | $29,808 | $10,695 | 35.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 576 | 916 | $82,440 | $10,434 | 12.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 76 | 78 | $25,974 | $8,484 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 62 | 66 | $12,012 | $4,914 | 40.9% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 73 | 73 | $25,039 | $4,177 | 16.7% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 22 | 22 | $11,902 | $3,816 | 32.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $8,432 | $2,815 | 33.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $9,545 | $2,471 | 25.9% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 30 | 30 | $24,120 | $1,847 | 7.7% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Facility | 2023 | 17 | 17 | $8,585 | $1,630 | 19.0% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 84 | 84 | $8,652 | $1,327 | 15.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 49 | 49 | $7,938 | $1,165 | 14.7% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 13 | 13 | $11,024 | $992.31 | 9.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 17 | 17 | $19,684 | $974.78 | 5.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 142 | 146 | $14,472 | $965.85 | 6.7% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 84 | 84 | $5,880 | $882.26 | 15.0% |
| 93320 | Ultrasound of heart blood flow, valves and chambers | Office | 2023 | 25 | 25 | $4,275 | $336.03 | 7.9% |
| 93923 | Complete ultrasound study of arm and leg arteries | Office | 2023 | 13 | 13 | $1,573 | $233.74 | 14.9% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Office | 2023 | 28 | 28 | $952.00 | $65.52 | 6.9% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 13 | 13 | $631.92 | $33.08 | 5.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 592 | 1,061 | $284,348 | $102,963 | 36.2% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2022 | 324 | 334 | $206,242 | $17,374 | 8.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 127 | 185 | $34,040 | $10,997 | 32.3% |
About Dr. Adam Schussheim, M.D
Dr. Adam Schussheim, M.D is a Cardiovascular Disease healthcare provider based in Fairfield, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/17/2005. The National Provider Identifier (NPI) number assigned to this provider is 1104821925.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Adam Schussheim, M.D has received a total of $146,029 in payments from pharmaceutical and medical device companies, with $122,339 received in 2024. These payments were reported across 67 transactions from 13 companies. The most common payment nature is "" ($122,339).
As a Medicare-enrolled provider, Schussheim has provided services to 9,471 Medicare beneficiaries, totaling 13,225 services with total Medicare billing of $714,607. Data is available for 4 years (2020–2023), covering 87 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Hypertension Specialist, Nuclear Cardiology
- Location Fairfield, CT
- Active Since 06/17/2005
- Last Updated 02/13/2018
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1104821925
Products in Payments
- PRALUENT ALIROCUMAB INJECTION (Biological) $13,877
- PRALUENT (Drug) $5,340
- PRALUENT (Biological) $3,902
- ELIQUIS (Drug) $165.45
- JARDIANCE (Drug) $124.56
- OPSUMIT MACITENTAN (Drug) $56.22
- ENTRESTO (Drug) $40.29
- Corlanor (Drug) $34.54
- EVKEEZA (Biological) $18.99
- CardioMEMS HF System (Device) $13.94
- CHANTIX (Drug) $12.66
- XARELTO (Drug) $11.28
- KYNAMRO (Drug) $11.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Fairfield
Robert Winslow, M.d, M.D
Cardiovascular Disease — Payments: $155,333
Cardiovascular Disease $155,333
Dr. Lynne Wagoner, Md, MD
Cardiovascular Disease — Payments: $151,998
Cardiovascular Disease $151,998
Dr. Ho-Hin Choy, M.d, M.D
Cardiovascular Disease — Payments: $66,203
Cardiovascular Disease $66,203
Ram Gordon, Md, MD
Cardiovascular Disease — Payments: $31,625
Cardiovascular Disease $31,625
Dr. Milind Dhond, M. D, M. D
Cardiovascular Disease — Payments: $22,399
Cardiovascular Disease $22,399
Jeffrey Breneisen, Md, MD
Cardiovascular Disease — Payments: $19,530
Cardiovascular Disease $19,530